FDA Clearance Tracker · P160045-S031
Oncomine Dx Target Test
Last checked: Nov 20, 2026Latest source record: Sep 21, 2022 (this decision)Source: openFDAMethods & limitations
Decided
Sep 21, 2022
Approved
Time to decision
362 days
Received Sep 24, 2021. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P160045-S031
- Device name
- Oncomine Dx Target Test
- Applicant
- Life Technologies Corporation
- Applicant location
- Carlsbad, CA
- Received
- Sep 24, 2021
- Decided
- Sep 21, 2022
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P160045
Device type
- Device type
- Next generation sequencing oncology panel, somatic or germline variant detection system (PQP)
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval to expand the intended use of the Oncomine Dx Target Test to include a companion diagnostic indication for the detection of the identification of RET fusions in NSCLC patients, RET mutations in medullary thyroid cancer (MTC) patients and RET fusions in thyroid cancer (TC) patients who may benefit from RETEVMO® (selpercatinib).
Source documents
Other decisions for Life Technologies Corporation
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K260827 · Decided Oct 15, 2026 · 216 days after receipt
Device type: High Throughput Sequencing Based Tumor Profiling Test Of Circulating Cell-Free Nucleic Acids (SBY) · Laboratory Medicine & Pathology
- Oncomine Dx Express TestPMA supplement
P240040-S005 · Decided Sep 9, 2026 · 180 days after receipt · Panel Track
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
P240040 · Decided Jul 2, 2025 · 232 days after receipt
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.